Table 4: Blood level omega-3 polyunsaturated fatty acids versus high-grade prostate risk random effect analysis model.

Groups Effect estimates and 95% confidence intervalPublication bias
Omega-3 derivatives Number of study valuedf value Point estimatesLower limitUpper limit valueBeggEgger

ALA57.73140.10248.2640.9650.6051.5380.8810.8070.870
DHA58.59340.07253.4491.2330.7691.9780.3850.2210.051
DHA44.31030.23030.3891.4620.9722.1990.0680.7340.265
DPA33.29120.19339.2310.5970.2991.1930.1441.0000.930
EPA58.36240.07952.1621.1300.7171.7810.5990.2210.273
EPA43.93130.26923.6751.3170.9101.9080.1450.7340.952
(DHA + DPA + EPA)*20.370100.02650.9081.2320.9551.5900.108
(DHA + EPA)*8.49870.29117.6291.3811.0501.8170.021
Total omega-3*29.708150.01349.5081.1650.9311.4570.181

Interstudy heterogeneity was tested by Cochrane’s (Chi2) at a significance level of and quantified by , where % is considered to be evidence of substantial heterogeneity and ≥75%, considerable heterogeneity.
Interstudy variation adjusted (heterogeneous study removed from the pool of effect estimates).
*Generated from adjusted total effect estimates from each PUFA random effect analysis.